Galera Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler downgraded Galera Therapeutics to Neutral from Overweight with a price target of 50c, down from $6. The FDA issued a Complete Response Litter for avasopasem for the prevention of severe oral mucositis caused by radiation therapy for head and neck cancer and said an additional clinical trial would be required the analyst tells investors in a research note. The firm downgraded the shares on the news.